Ignite Creation Date:
2024-05-06 @ 3:50 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04777708
Status:
TERMINATED
Last Update Posted:
2023-03-24
First Post:
2021-02-25
Brief Title:
BO-112 and Pembrolizumab for the Treatment of PD-1PD-L1 Refractory Liver Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Organization Data
Organization:
Jonsson Comprehensive Cancer Center
Class:
OTHER
Study ID:
21-000276
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Highlight Therapeutics | INDUSTRY |
| Merck Sharp Dohme LLC | INDUSTRY |